Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency

Subcutaneous human IgG (SCIG) therapy in primary immunodeficiency (PID) offers sustained IgG levels throughout the dosing cycle and fewer adverse events (AEs) compared to intravenous immunoglobulin (IVIG). A phase I study showed good local tolerability of IgPro20, a new 20% liquid SCIG stabilized wi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hagan, John B., Fasano, Mary B., Spector, Sheldon, Wasserman, Richard L., Melamed, Isaac, Rojavin, Mikhail A., Zenker, Othmar, Orange, Jordan S.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2935975/
https://ncbi.nlm.nih.gov/pubmed/20454851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10875-010-9423-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados